• In late June 2026, HCA Healthcare, Inc. was removed from several Russell growth benchmarks, including the Russell Top 200 Growth and Russell 1000 Growth indexes, reflecting a reclassification of the stock’s style exposure rather than an operational change.
• At the same time, HCA is committing about US$5.5–US$6.0 billion to expand hospital and emergency capacity and advancing gene-editing research in severe blood disorders, underscoring a focus on large-scale growth projects and complex clinical care capabilities.
• We’ll now explore how this combination of index removal and multibillion-dollar capacity expansion could reshape HCA Healthcare’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

HCA Healthcare Investment Narrative Recap

To hold HCA Healthcare, you need to be comfortable owning a large, capital intensive hospital operator that depends on stable policy support, disciplined cost control and consistent patient volumes. The recent removal from several Russell growth indexes mainly affects how some funds may hold the shares, not the underlying business. Near term, the biggest catalyst remains execution on HCA’s large project pipeline, while the key risk is policy and reimbursement pressure, particularly around Medicaid and supplemental programs.

The most relevant recent development alongside the index changes is HCA’s approval of US$5.5–US$6.0 billion of capital projects over the next 24–30 months. These projects, aimed at expanding beds, emergency capacity and outpatient reach, sit right at the heart of the current catalyst story, but they also raise the execution and cost risk that could weigh on margins if timelines slip or expenses run higher than expected.

Yet behind this expansion push, investors should be aware of the growing risk that rising professional fees and policy shifts could...

HCA Healthcare's narrative projects $88.2 billion revenue and $7.5 billion earnings by 2029.

Uncover how HCA Healthcare's forecasts yield a $503.57 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already projecting only about 4.5 percent annual revenue growth to roughly US$87.2 billion by 2029 and thinner margins, so you should expect that fresh news like HCA’s index removal and multi billion dollar build out could shift those cautious views and it is worth comparing how your own expectations line up with both the optimistic and pessimistic cases.

Explore 3 other fair value estimates on HCA Healthcare - why the stock might be worth just $503.57!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your HCA Healthcare research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free HCA Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HCA Healthcare's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.